UNSPSC 51393301: Nardeterol

This classification denotes a beta-adrenergic agonist with the molecular formula C20H24FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70859437W3, chemically known as benzenemethanol, alpha-(((3-(1h-benzimidazol-1-yl)-1,1-dimethylpropyl)amino)methyl)-2-fluoro-4-hydroxy- but generally known as nardeterol, which bears US NIH Compound Identifier 68918. European Medicines Agency schedules Nardeterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09165MIG.

UNSPSC 51393301 Nardeterol is a Commodity code that covers pharmaceutical products for emergency response and harm-reduction applications, specifically naloxone and drug deactivation systems. State and local health authorities and public-health jurisdictions are the primary buyers under this code, procuring naloxone supplies and associated deactivation equipment to support community health and overdose-prevention initiatives. Solicitations are issued as competitive sealed bids (IFB) with annual or multi-year terms and quarterly delivery schedules to health facilities or central distribution points. Recent activity shows health departments and county-level health agencies directing procurement through their purchasing offices, with vendors required to meet standard compliance standards including E-Verify verification, drug-free workplace certification, and insurance coverage for workers' compensation and general liability.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023, and quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, which signals state-level interest in reshaping pharmaceutical distribution channels outside traditional pharmacy benefit manager and wholesaler networks. Recent opportunities cluster in Florida and Texas, with health department and HHS procurement offices leading activity. Vendors must provide fixed-unit pricing, include shipping and delivery in proposals, and accept three-month probationary periods with termination flexibility for the county; FEMA funding potential introduces federal compliance obligations including Clean Air Act and Federal Water Pollution Control Act adherence.